Summary Both lymphokine activated killer (LAK) cells and specific cytotoxic T lymphocytes appear to play a role in tumour immunity. Tumour infiltrating lymphocytes (TIL) which display a CD56+ phenotype (both CD3+ and CD3-) are also likely to possess anti-tumour activity. We have previously described a 120 kDa surface antigen, termed LAK1, expressed on a subset of human peripheral blood lymphocytes (20-50%) with both NK and LAK activity. The aim of the present study was to determine whether LAKI antigen is able to distinguish among TIL two populations of effector cells displaying either specific or non MHC-restricted (NK/LAK) activity. We showed that about 25% of freshly derived TIL were weakly stained with anti-LAKl monoclonal antibody and most of them were also CD3+CD56-. After culture in recombinant interleukin-2 the majority of TIL were CD3+CD56-and the percentage of LAK1 + cells increased up to 50%. Among cloned TIL, only those lacking LAKI antigen displayed a specific cytotoxicity against the autologous tumour, whereas the non-lytic clones were able to produce both tumour necrosis factor and gamma-interferon. Moreover, when TIL from a renal cell carcinoma were fractionated into LAK I -and LAK I + populations, the specific lytic activity was mainly evident when LAKI -lymphocytes were used as effector cells. Conversely, LAK activity was confined to the LAK1+ subset.
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It has been reported that both lymphokine activated killer (LAK) cells and specific cytotoxic T lymphocytes (CTL) play a role in tumour immunity (Muul et al., 1987; Belldegrun et al., 1988) . Tumour infiltrating lymphocytes (TIL) derived from a number of human solid tumours and grown in the presence of recombinant interleukin-2 (rIL2) were shown to mediate anti-tumour cytotoxicity in vitro. This cytotoxicity was reported to be specific for autologous melanomas and some lung tumours (Muul et al., 1987; Itoh et al., 1988) . Nevertheless other studies failed to confirm the major histocompatibility complex (MHC)-restricted killing of fresh tumour cell targets by IL2-activated human TIL (Belldegrun et al., 1988; Whiteside et al., 1988) . Moreover, TIL bearing the CD56 antigen (both CD3+ and CD3-) are also likely to possess anti-tumour activity (Lanier & Phillips, 1986) .
It remains unclear which population (T, NK, LAK) is responsible for anti-tumour immunity and whether or not a specific antigen recognition (MHC-restricted and T cell mediated) is required. We have previously described a surface antigen expressed on a subset of human peripheral blood lymphocytes (PBL) with both NK and LAK activity (Zocchi et al., 1987) ; a fraction (one-third) of LAKI + cells coexpressed surface markers (CD3 and CD4 or CD8) of the T cell lineage (Zocchi et al., 1989 (Zocchi et al., 1987) followed by FITC-conjugated goat anti-mouse IgG (Cappel, Cochranville, PA, USA). Double staining was performed by direct immunofluorescence using FITC-Leu4 plus Phycoerythrin (PE)-conjugated Leul9 MoAbs or indirect immunofluorescence with LAKI MoAb, FITC-goat anti-mouse IgG2a (Cappel) followed by PE-Leu4 or PE-Leul9. MoAbs used for staining were purchased from Becton Dickinson, with the exception of anti-LAKI MoAb. Cytolytic activity was evaluated in a standard 4 h 51Cr release assay using autologous and allogeneic fresh tumour cells, the NK-sensitive K562 cell line and two NKresistant cell lines (Mel 10 and Epa 1) as targets. Lectindependent cellular cytotoxicity (LDCC) was performed with 5 tLg ml-' phyto-haemoagglutinin (PHA, Sigma Chemicals Co., St Louis, MO, USA) and the P815 murine cell line as target. All the experiments were performed at different effector:target (E:T) ratios (from 30:1 to 3:1). The results were expressed either as lytic units per 106 cells (Henney, 1971) Moretta et al. (1983) . Briefly, TIL from a renal cell carcinoma (RCC) cultured for 10 days in 25 U ml1I rIL2, were seeded (10-0.5 cells per well) in U-bottomed microwell plates in the presence of irradiated autologous splenocytes as feeder cells and 25 U ml1' rIL2. The cloning frequency, calculated according to Taswell (1981) , was 1/3.2, in keeping with data from other laboratories (Whiteside et al., 1988) . Growing clones were expanded in rIL2 (25 U ml-') and subsequently tested for phenotype and function.
LAKI+ and LAKI-populations were fractionated by rosetting with ox erythrocytes coated with affinity-purified goat anti-mouse Ig (Ramarli et al., 1987) . LAKI+ cells contaminating the LAKI+ fractions were less than 3%.
Quantitation of xTNF and y-IFN was performed as previously described. Briefly, clones were washed twice in RPMI 1640 and cultured for 36 h with 1% Phytohaemoagglutinin (PHA Sigma Chemicals Co., 10 g ml-' final dilution) at 5 x 104 cells per microwell. Cell-free supernatants (SN) were collected and tested for y-IFN and a-TNF activity. Gamma-IFN Units were determined using vescicular stomatitis virus infected human amniotic (FL) cells in a 50% cytopathic effect reduction assay (Melioli et al., 1985) . Gamma-IFN titres present in the SN were evaluated as the reciprocal of the highest dilution giving 50% reduction of the cytopathic effect in infected control cultures. U ml-' of y-IFN were calculated in comparison with T-IFN titres of a standard curve. Alpha-TNF activity was tested evaluating the cytopathic effect of SN from TIL clones on Actinomycin-D (Sigma) treated WEHI 164 sarcoma cells in a 5'Cr release assay (Colotta et al., 1985) . SN-induced specific lysis of 5'Cr-labelled WEHI 164 cells was compared with lysis obtained using purified a-TNF (T Cell Sciences Inc., Cambridge, MA, USA). Picograms ml-' of ax-TNF were calculated on the basis of a standard curve.
Results
Phenotype andfunction of bulk cultured TIL TIL obtained from lung and renal tumours grew successfully in rIL2 independent of the concentration (25 or 1,000 U ml-') and they were easily expanded over a period of 3-4 weeks. Phenotypic analysis showed that 45% of freshly derived TIL were CD4+ whereas 27% were CD8+. LAKI antigen was weakly expressed on about 25% of TIL most of which (>75%) were also CD3+CD56-. After culture in rIL2, the percentage of LAKI+ TIL increased to 50%, and these cells expressed either the CD3 (50-60%) or CD56 (20-30%) molecule. We further evaluated the co-expression of CD3 and CD56 surface antigens on fractionated LAKI+ and LAK I-cultured TIL. As shown in Figure 1 , CD3 + CD56+ cells represented about 35% of LAKI+ TIL ( Figure  la) and 17% of LAKI -cells (Figure lb) respectively. Moreover, TIL cultured in 25 U ml-' rIL2 contained predominantly CD4+ cells, whereas a higher percentage of CD8+ lymphocytes was observed in the presence of 1,000 U ml-' rIL2 (Table I) . When the lytic activity of unfractionated TIL was analysed, using autologous and allogeneic tumours, and the K562 cell line as targets, a specific cytotoxicity was observed only in two cases. No significant difference between low and high doses of the lymphokine in terms of induction of cytotoxicity against fresh autologous tumours was evident in most cases; conversely NK activity was constantly higher after culturing effector cells with 1,000 U ml-' rIL2 (not shown). We could not detect any relationship between phenotypic or functional pattern of TIL and their source (lung or kidney cancer).
Cloning of TIL To characterise further the effector cells among TIL, clonal analysis by limiting dilution was carried out, and the growing clones were analysed with regard to their lytic activity, lymphokine production and expression of LAKI antigen.
Ten clones (out of 21 tested) did not exert any type of cytotoxicity whereas eleven clones displayed high lytic potential in LDCC (Table II) . The majority of these clones (9/11) were LAK1+, six were also CD4+ while four expressed the CD8 antigen and one was CD4-CD8-. Surprisingly, none of the 11 clones showing LDCC was able to kill the fresh allogeneic tumour nor the NK-resistant Mel 10 and Epal cell lines. Conversely, two clones displayed a significant killing of the autologous tumour and both of them lacked the LAKI antigen (Figure 2a) . It is of note that only one clone, showing CD3+WT31-phenotype, killed the NK-sensitive K562 cell line ( Figure 2a and Table II ). Moreover, we observed that all LAKI+ TIL clones produced high amounts of both a-TNF and y-IFN upon stimulation with PHA, whereas the LAKdid not (Figure 2b ).
Fractionation of LAKIJ and LAKI-TIL
In order to confirm the hypothesis that LAKI antigen might dissect TIL into specific CTL and NK/LAK cells, TIL from a RCC were fractionated into LAK1 + and LAK1 -cells by immunorosetting and tested for their lytic activity against autologous or allogeneic tumour targets and the K562 cell line. Lysis of the autologous tumour was mainly evident when LAK1 -TIL, cultured both with low and high doses of rIL2, were used as effector cells. On the other hand LAK activity was present only when 1,000 U ml-' rIL2 were used, and was confined to the LAK1 + subset (Table III) . As shown in Figure Ib , LAKI -subset was mainly represented by CD3+CD56-cells, whereas one-third of LAKI + TIL ( Figure  la) the presence of 25 U ml-' or 1,000 U ml-rIL2.
Discussion
The aim of our study was to determine whether LAK I antigen is able to distinguish among TIL obtained from different solid tumours, two populations of effector cells with either specific or LAK activity. We first analysed the distribution of the LAKl molecule on TIL, and found that about 25% of freshly derived TIL were weakly stained with anti-LAKI MoAb. As previously reported (Zocchi et al., 1989) A clonal analysis of TIL from a RCC showed that the majority of the clones were CD4+, LAKI+ and displayed high lytic potential in LDCC (Table II) . Nevertheless only one clone was able to kill K562 target cells and none of the clones tested killed the allogeneic tumour. Interestingly, the clone with NK activity showed a CD3+WT31-phenotype consistent with data from other laboratories supporting the notion that gamma' delta' T lymphocytes are able to exert non MHC-restricted cytotoxicity (Borst et al., 1987) . Two clones displayed a slight but significant specific lysis and both of them were LAKI -. Furthermore, unlike LAKI -clones, all LAK I' TIL clones produced high amounts of ox-TNF and y-IFN upon stimulation with PHA ( Figure 2b) . Recently, it has been reported that tumour cell lines stimulate LAK cells to produce factors, in particular y-IFN and TNF, with slow acting cytotoxic activity (Chong et al., 1989) .
LAK I + clones might exert their anti-tumour activity throughout this mechanism rather than killing tumour targets by direct cell to cell contact. On the basis of these data we were able to hypothesise that, among TIL, specific cytotoxic lymphocytes were confined to the LAK1-population, whereas cells expressing LAK1 antigen were responsible for LAK activity. In order to substantiate this hypothesis, TIL from a RCC were fractionated into LAKI+ and LAK1-cells and tested for their lytic activity against autologous or allogeneic tumour targets and the NK-sensitive K562 cell line. Lysis of the autologous tumour was mainly evident when LAK1 -TIL, cultured with both low and high doses of rIL2, were used as effector cells.
On the other hand LAK activity was present only when 1,000 U ml1 1 rIL2 were used and was confined to the LAK1+ subset (Table III) Nevertheless, the LAKI MoAb may represent a useful tool for studying the relationship between T lymphocytes and tumour cells. Further studies to define cellular and biological characteristics of TIL, both at the population and at the clonal level, are in progress.
